Join to view full profile
11100 Euclid AveCleveland, OH 44106
Phone+1 216-844-3951
Fax+1 216-767-8778
Dr. Sharma is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2010 - 2011- University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2010
Cook County Health and Hospitals SystemResidency, Internal Medicine, 2005 - 2008
G.S.V.M Medical College KanpurClass of 2003
Certifications & Licensure
VA State Medical License 2023 - 2026
OH State Medical License 2011 - 2022
NY State Medical License 2010 - 2012
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Rhapsody Integration Engine, Orion Health, 2015-2017
- CMS Meaningful Use Stage 2 Certification Allscripts FollowMyHealth, Allscripts, 2015-2017
- CMS Meaningful Use Stage 1 Certification Allscripts FollowMyHealth, Allscripts, 2015-2017
Clinical Trials
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
- Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Publications & Presentations
PubMed
- 11 citationsPhase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumorsJennifer R. Eads, Smitha S. Krishnamurthi, Joel N. Saltzman, Joseph A. Bokar, P. Savvides
Investigational New Drugs. 2021-02-01 - 96 citationsPhase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors:Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck
Therapeutic Advances in Medical Oncology. 2019-06-21 - 46 citationsRetinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.Priyanka Bhateja, Michelle Chiu, Gary Wildey, Mary Beth Lipka, Pingfu Fu
Cancer Medicine. 2019-04-01
Press Mentions
Adopt Dairy Farming with Focus on Value Addition of Milk: SKUAST-VCJuly 11th, 2020
SKUAST-J Celebrates World Food DayOctober 16th, 2017
In the Clinic: Ongoing Clinical Trials Evaluating C-MET-Inhibiting DrugsNovember 1st, 2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
